Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Determining the duration of therapy for patients with community-acquired pneumonia.

Scalera NM, File TM Jr.

Curr Infect Dis Rep. 2013 Apr;15(2):191-5. doi: 10.1007/s11908-013-0327-3.

PMID:
23443362
2.

Short-course antimicrobial therapy for community-acquired pneumonia.

Kolditz M, Halank M, Höffken G.

Treat Respir Med. 2005;4(4):231-9. Review.

PMID:
16086597
3.

Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia.

Avdic E, Cushinotto LA, Hughes AH, Hansen AR, Efird LE, Bartlett JG, Cosgrove SE.

Clin Infect Dis. 2012 Jun;54(11):1581-7. doi: 10.1093/cid/cis242. Epub 2012 Apr 10.

PMID:
22495073
4.

Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.

File TM Jr.

Clin Infect Dis. 2004 Sep 1;39 Suppl 3:S159-64. Review.

PMID:
15546111
5.

Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.

Li JZ, Winston LG, Moore DH, Bent S.

Am J Med. 2007 Sep;120(9):783-90.

PMID:
17765048
6.

Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.

Arnold FW, LaJoie AS, Brock GN, Peyrani P, Rello J, Menéndez R, Lopardo G, Torres A, Rossi P, Ramirez JA; Community-Acquired Pneumonia Organization (CAPO) Investigators.

Arch Intern Med. 2009 Sep 14;169(16):1515-24. doi: 10.1001/archinternmed.2009.265.

PMID:
19752410
7.

Application of antimicrobial stewardship to optimise management of community acquired pneumonia.

Bosso JA, Drew RH.

Int J Clin Pract. 2011 Jul;65(7):775-83. doi: 10.1111/j.1742-1241.2011.02704.x. Review.

PMID:
21676120
8.

Community-acquired pneumonia.

Cassiere HA, Niederman MS.

Dis Mon. 1998 Nov;44(11):613-75. Review.

PMID:
9858958
9.

Antibiotic stewardship in community-acquired pneumonia.

Viasus D, Vecino-Moreno M, De La Hoz JM, Carratalà J.

Expert Rev Anti Infect Ther. 2017 Apr;15(4):351-359. doi: 10.1080/14787210.2017.1274232. Epub 2016 Dec 27.

PMID:
28002979
10.

Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.

Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH; Community-Acquired Pneumonia Recovery in the Elderly Study Group.

Clin Infect Dis. 2006 Jan 1;42(1):73-81. Epub 2005 Nov 22. Erratum in: Clin Infect Dis. 2006 May 1;42(9):1350.

PMID:
16323095
11.

How long should we treat community-acquired pneumonia?

Scalera NM, File TM Jr.

Curr Opin Infect Dis. 2007 Apr;20(2):177-81. Review.

PMID:
17496577
12.

Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis.

Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME.

Drugs. 2008;68(13):1841-54.

PMID:
18729535
13.

Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis.

Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W.

Respir Med. 1998 Aug;92(8):1032-9.

14.

Community-acquired pneumonia in the elderly.

Fung HB, Monteagudo-Chu MO.

Am J Geriatr Pharmacother. 2010 Feb;8(1):47-62. doi: 10.1016/j.amjopharm.2010.01.003. Review.

PMID:
20226392
15.

Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.

Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ.

Pediatr Infect Dis J. 2007 Oct;26(10):868-78.

PMID:
17901791
16.

Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.

Pertel PE, Bernardo P, Fogarty C, Matthews P, Northland R, Benvenuto M, Thorne GM, Luperchio SA, Arbeit RD, Alder J.

Clin Infect Dis. 2008 Apr 15;46(8):1142-51. doi: 10.1086/533441.

PMID:
18444848
17.
18.

Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.

Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.

Clin Ther. 2008 Feb;30(2):358-71. doi: 10.1016/j.clinthera.2008.01.023.

PMID:
18343274
19.
20.

Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience.

Ioachimescu OC, Ioachimescu AG, Iannini PB.

Int J Antimicrob Agents. 2004 Nov;24(5):485-90.

PMID:
15519482

Supplemental Content

Support Center